Mavacamten
Mavacamten has been studied in 3 papers since 2026: 1 observational study in people, 2 in cells; 3 in the past year. The newest paper, Nov 1, 2026: “Human Living Myocardial Slice Model for Load-Dependent Pharmacologic Testing in Hypertrophic Cardiomyopathy”.
3 papers study it2 findingsUpdated
3 new papers in 30 daysSee all 3 papers on mavacamten
At a glance
The findings reach cells, none yet in people. 2 independent labs in 2 countries; 2 trials, none about aging.
None of its findings points the other way.
- 2 independent labs in 2 countries
- 2 trials, none about aging
- Funders: National Cancer Institute and 4 more
- Humans1
- Cells2
What did studies of mavacamten find?
2Studies of mavacamten measured 2 outcomes; the most studied are myocardial work (1 study) and contraction stress (1).
Myocardial work
downin human cells1
1 study
Myocardial work
downin human cells1
Mavacamten decreases myocardial work in human cells.
“Mavacamten, sotagliflozin, and empagliflozin decreased work.”
Cellsliving myocardial slices
JACC. Basic to translational science
Contraction stress
downin human cells1
1 study
Contraction stress
downin human cells1
Mavacamten decreases contraction stress in human cells (SAGA organoids) (0.606 → 0.300 mN/mm2).
“0.9 μM Mavacamten reduced contraction stress (0.606 → 0.300 mN/mm2, p < 0.0001).”
CellsSAGA organoidscardiac organoid0.9 μM
A novel stepwise autonomous guided assembly approach for engineered cardiac organoid formation
ESC Congress 2026 abstract
Trial sponsors
1 trial75 people